Black and Asian patients have increased risk of severe COVID-19 at different stages of the disease

Credit: Unsplash / CC0 Public Domain

Prime Minister Justin Trudeau assured Canadians on Friday that the turbulent rollout of the COVID-19 vaccine in the country remains on track after Pfizer agreed to increase shipments once Moderna shipments stalled.

“We’re on track to hit the top 40 to 50 million doses by the end of June,” Trudeau told a news conference, adding that by that date, “most Canadians will be able to get an initial dose of the Get vaccination. ” . “

He also renewed his government’s commitment that “all Canadians who want a vaccine can be vaccinated by the end of September”.

Previously, Minister of Procurement Anita Anand had announced that Moderna would reduce almost half of its next delivery, which is expected by the end of the month, to 650,000 cans.

However, Trudeau said Canada received an additional eight million doses of Pfizer BioNTech to more than make up for the Moderna deficiency.

Canada will “continue to bring vaccines into the country in the face of volatile supply chains,” said Anand.

“There may be additional delays in the coming months,” which “is obviously very disappointing,” she added.

The first four million additional Pfizer BioNTech doses are expected to arrive in May, followed by two million doses in June and two million more doses in July, Trudeau said.

Canada has signed contracts with seven pharmaceutical companies for approximately 400 million COVID-19 vaccine doses and approved four for use – the Pfizer, Moderna AstraZeneca, and Johnson & Johnson jabs.

To date, more than 8.5 million Canadians, or 22.5 percent of the population, have received at least one shot, according to the COVID-19 Vaccination Tracker website.

Follow the latest news on the Coronavirus (COVID-19) outbreak

© 2021 AFP

Quote: Pfizer Sends More COVID Vaccines to Canada as Moderna Jabs Delays (2021, April 16) April 17, 2021 from https://medicalxpress.com/news/2021-04-pfizer-covid-vaccines-canada-moderna .html

This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.